The customary approach to early-phase clinical trial design, where the focus is on identification of the maximum tolerated dose, is not always suitable for noncytotoxic or other targeted therapies.
Protocol design does not struggle in the protocol. It struggles in the transition to trial, when assumptions embedded in the ...
Riluzole is a glutamate-modulating agent with neuroprotective properties approved for use in amyotrophic lateral sclerosis. The efficacy and safety of riluzole vs placebo as an adjunct to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results